



**SOUTH CAROLINA REVENUE AND FISCAL AFFAIRS OFFICE**  
**STATEMENT OF ESTIMATED FISCAL IMPACT**  
**(803)734-3780 • RFA.SC.GOV/IMPACTS**

*This fiscal impact statement is produced in compliance with the South Carolina Code of Laws and House and Senate rules. The focus of the analysis is on governmental expenditure and revenue impacts and may not provide a comprehensive summary of the legislation.*

---

<b>Bill Number:</b>	H. 4568	Introduced on January 11, 2022
<b>Author:</b>	Oremus	
<b>Subject:</b>	Chemically-Induced Abortions, Disclosure Requirements	
<b>Requestor:</b>	House Judiciary	
<b>RFA Analyst(s):</b>	Wren	
<b>Impact Date:</b>	March 22, 2022	

---

### **Fiscal Impact Summary**

This bill requires a disclosure statement to be provided to a pregnant woman who is administered, dispensed, or otherwise provided mifepristone, which is the first drug used in a two-drug process to induce a chemical abortion. The disclosure statement must include specified language regarding misoprostol, which is the second drug used in a two-drug process to induce a chemical abortion.

This bill will have no expenditure impact on the Department of Health and Environmental Control (DHEC) since it does not alter the duties or responsibilities of the agency.

The expenditure impact of this bill on the Medicaid program is pending, contingent upon a response from the Department of Health and Human Services (HHS).

### **Explanation of Fiscal Impact**

#### **Introduced on January 11, 2022**

##### **State Expenditure**

This bill requires a disclosure statement to be provided to a pregnant woman who is administered, dispensed, or otherwise provided mifepristone, which is the first drug used in a two-drug process to induce a chemical abortion. The disclosure statement must include specified language regarding misoprostol, which is the second drug used in a two-drug process to induce a chemical abortion. The disclosure statement must be attached to the package that contains the misoprostol, attached to a written prescription for misoprostol, or attached to the patient's discharged instructions if misoprostol is sent directly to the pharmacy.

**Department of Health and Environmental Control.** DHEC indicates that this bill does not alter the duties or responsibilities of the agency. Therefore, the bill will have no expenditure impact on the agency.

**Department of Health and Human Services.** We have reached out to HHS to determine if this bill will have an impact on the Medicaid program. Therefore, the expenditure impact is pending, contingent upon a response.

**State Revenue**


N/A

**Local Expenditure**

N/A

**Local Revenue**

N/A



Frank A. Rainwater, Executive Director